Amneal's European Licensing Deal for IPX203 with Zambon Biotech

Photo:Representative Image

Bridgewater's Amneal Pharmaceuticals, a global pharmaceutical company, announced that it has signed an exclusive license agreement for IPX203 in the European Union, United Kingdom, and Switzerland with Italy's Zambon Biotech SA, part of the Zambon Group (Zambon).

IPX203 is a new oral formulation of carbidopa/levodopa sustained-release (CD/LD) capsules for the treatment of Parkinson's disease (PD). We are evaluating it—food and Drug Administration (FDA). Zambon plans to seek regulatory approval and commercialize IPX203 in Europe. Financial terms of the deal were not disclosed.

Zambon is a chemical and pharmaceutical company founded in Italy in 1906. The founder's family still manages the company. Zambon has a significant presence in European neurology, including the launch and commercialization of Xadago (safinamide), used as an adjunct to LD to treat patients with variable PD. 

The IPX203 should fill our pocket with a PD spotlight in Europe, where it is. Amneal's strategic goal is to make our products available to patients in the United States and Parkinson's patients worldwide. As a family-owned company that shares our vision and long-term commitment to the patient community, Zambon is the right partner to expand IPX203 in Europe," said Chirag and Chintu Patel, co-CEO of Amneal.

"The mission of Zambon Biotech. It is to build a long-term portfolio of new medicines that improve patients' lives. Based on our group's commercial strength and staying power in neurology, particularly Parkinson's disease, we are delighted to work with Amneal to bring IPX203 to Parkinson's patients in Europe," said Frank Weber, CEO of Zambon Biotech.